Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
Jong‐Ho Cha, Li-Chuan Chan, Ying‐Nai Wang, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 4, pp. 101817-101817
Open Access | Times Cited: 18

Showing 18 citing articles:

Recent advances in therapeutic strategies for triple-negative breast cancer
Yun Li, Huajun Zhang, Yulia Merkher, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 460
Eph receptors and ephrins in cancer progression
Elena B. Pasquale
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 5-27
Open Access | Times Cited: 56
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 47
Eph Receptors in Cancer
Sakshi Arora, Andrew M. Scott, Peter W. Janes
Biomedicines (2023) Vol. 11, Iss. 2, pp. 315-315
Open Access | Times Cited: 26
Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer
Sara K. Jaradat, Nehad M. Ayoub, Ahmed H. Al Sharie, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access | Times Cited: 10
Crosstalk between the peripheral nervous system and breast cancer influences tumor progression
Jianming Hu, Wuzhen Chen, Lesang Shen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 6, pp. 188828-188828
Closed Access | Times Cited: 32
CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
John Maher, David M. Davies
Cancers (2023) Vol. 15, Iss. 4, pp. 1171-1171
Open Access | Times Cited: 18
Characteristics of the Immune Microenvironment and Progress in Immunotherapy for Triple-Negative Breast Cancer
书韬 贾
World Journal of Cancer Research (2025) Vol. 15, Iss. 01, pp. 24-38
Closed Access
The neuroscience in breast cancer: current insights and clinical opportunities
Jiafeng Wang, Meng-chuan Wang, Lei-Lei Jiang, et al.
Heliyon (2025), pp. e42293-e42293
Open Access
An Update on the General Features of Breast Cancer in Male Patients—A Literature Review
S Ionescu, Alin Codruț Nicolescu, M Marincaş, et al.
Diagnostics (2022) Vol. 12, Iss. 7, pp. 1554-1554
Open Access | Times Cited: 14
EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy
Iason Psilopatis, Eleni Souferi-Chronopoulou, Kleio Vrettou, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15275-15275
Open Access | Times Cited: 11
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
Diego F. Chamorro, Lauren K. Somes, Valentina Hoyos
Cancers (2023) Vol. 16, Iss. 1, pp. 124-124
Open Access | Times Cited: 5
Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma
Jae‐Hoon Kim, Won‐Sik Shin, Se-Ra Lee, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12195-12195
Open Access | Times Cited: 8
Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers
Praopim Limsakul, Pongsakorn Choochuen, Gorn Charupanit, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 403-403
Open Access | Times Cited: 4
Development of an Anti-EphB4 Monoclonal Antibody for Multiple Applications Against Breast Cancers
Ren Nanamiya, Hiroyuki Suzuki, Mika K. Kaneko, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2023) Vol. 42, Iss. 5, pp. 166-177
Open Access | Times Cited: 4
EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma
Wenyue Zhao, Lu Liu, Xuehao Li, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109031-109031
Closed Access | Times Cited: 7
EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets
Ioanna Ε. Stergiou, Stavros P. Papadakos, Anna Karyda, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3963-3963
Open Access | Times Cited: 4
Structural insights into EphA4 unconventional activation from prediction of the EphA4 and its complex with ribonuclease 1.
Yi‐Chuan Li, Hirohito Yamaguchi, Yen‐Yi Liu, et al.
PubMed (2022) Vol. 12, Iss. 10, pp. 4865-4878
Closed Access | Times Cited: 3
Page 1

Scroll to top